companiesCompany
Xencor
Xencor is an antibody-engineering company (XmAb Fc technology) developing 2+1 T-cell engagers for kidney cancer (ENPP3) and ovarian/germ-cell tumours (CLDN6).
XmAb819 (ENPP3×CD3) in clear-cell RCC with expansion cohorts in CRC, NSCLC, and papillary RCC during 2026 and a pivotal study planned 2027; XmAb541 (CLDN6×CD3) with confirmed partial responses in ovarian and germ-cell tumours. XmAb Fc technology is licensed into several approved antibodies.